Edgewise’s Early Cardiomyopathy Data Builds Case For A Blockbuster

The EDG-7500 results have seen the company’s share price rocket, thanks to a potential advantage over existing treatments for the rare heart condition hypertrophic cardiomyopathy.

Edgewise Therapeutics has unveiled impressive results from EDG-7500, a novel treatment for the heart condition, obstructive hypertrophic cardiomyopathy (oHCM), with early safety and efficacy data exceeding expectations.

Analysts are now forecasting peak annual sales of $2bn or more for the product by the mid-2030s, if approved, and Edgwise’s share price is currently up by two-thirds

Key Takeaways

EDG-7500 was discovered as a by-product of Edgewise’s search for muscular dystrophy drugs – but could now be on a path towards blockbuster status

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

05 May 2025

• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

05 May 2025

• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives

05 May 2025

• By Mandy Jackson

Restructuring Edition: Unity unveiled more Phase IIb data for lead asset UBX1325 along with plans to shed its workforce while seeking a partner for it and other drugs. Also, Ono is consolidating US employees at one site, Entrada is cutting its workforce by 20% and other recent strategic shifts.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.